Literature DB >> 400821

In vitro and in vivo studies with BL-S786, cefoxitin, and cefamandole.

S Shadomy, G Wagner, M Carver.   

Abstract

The in vitro antimicrobial activities of BL-S786, cefoxitin, and cefamandole against 90 isolates of Enterobacteriaceae, including Escherichia coli, Klebsiella pneumoniae, Proteus mirabilis, Enterobacter cloacae and E. aerogenes, were studied by using an agar dilution procedure. Comparison of geometric mean minimal inhibitory concentrations showed that BL-S786 was half as active as cefamandole against Enterobacter species, 2 to 4 times more active than cefamandole against all other species, and 4 to 25 times more active than cefoxitin against all species. In vivo experiments employed acute protection tests in infected mice, using five isolates each of the five genera. Drugs were administered intramuscularly in two doses 3 h apart at dosages of 2.5, 5, 10, 20, and 40 mg per mouse. In most instances, BL-S786 was the most efficacious drug, being some 1.3 to 9.1 times more active than cefoxitin in all experiments and 1.5 to 8.7 times more active than cefamandole in most experiments. BL-S786 and cefamandole were comparable in activity in experiments with E. aerogenes, whereas BL-S786 was superior in experiments with E. cloacae.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 400821      PMCID: PMC352254          DOI: 10.1128/AAC.13.3.412

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  11 in total

1.  BL-S786, a new parenteral cephalosporin. II. In vitro antimicrobial activity comparison with six related cephalosporins.

Authors:  R N Jones; C Thornsberry; A L Barry; P C Fuchs; T L Gavin; E H Gerlach
Journal:  J Antibiot (Tokyo)       Date:  1977-07       Impact factor: 2.649

2.  BL-S786, a new parenteral cephalosporin. I. A collaborative in vitro susceptibility comparison to cephalothin against 5,762 clinical bacterial isolates.

Authors:  R N Jones; P C Fuchs; T L Gavan; E H Gerlach; A Barry; C Thornsberry
Journal:  J Antibiot (Tokyo)       Date:  1977-07       Impact factor: 2.649

3.  In vitro comparison of cefoxitin, cefamandole, cephalexin, and cephalothin.

Authors:  T C Eickhoff; J M Ehret
Journal:  Antimicrob Agents Chemother       Date:  1976-06       Impact factor: 5.191

4.  In vitro studies with cephanone.

Authors:  S Shadomy; C Kirchoff; G Wagner
Journal:  Antimicrob Agents Chemother       Date:  1974-12       Impact factor: 5.191

5.  An in vivo comparison of cefoxitin, a semi-synthetic cephamycin, with cephalothin.

Authors:  J M Hamilton-Miller; D W Kerry; W Brumfitt
Journal:  J Antibiot (Tokyo)       Date:  1974-01       Impact factor: 2.649

6.  In vitro susceptibility of cephalothin-resistant Enterobacteriaceae to cefoxitin and BL-S786.

Authors:  R D Meyer
Journal:  J Antibiot (Tokyo)       Date:  1977-04       Impact factor: 2.649

7.  In vitro evaluation of cefoxitin and cefamandole.

Authors:  H G Adams; G A Stilwell; M Turck
Journal:  Antimicrob Agents Chemother       Date:  1976-06       Impact factor: 5.191

8.  Laboratory evaluation of BL-S786, a cephalosporin with broad-spectrum antibacterial activity.

Authors:  F Leitner; M Misiek; T A Pursiano; R E Buck; D R Chisholm; R G DeRegis; Y H Tsai; K E Price
Journal:  Antimicrob Agents Chemother       Date:  1976-09       Impact factor: 5.191

9.  Biological properties of three 3-heterocyclic-thiomethyl cephalosporin antibiotics.

Authors:  W E Wick; D A Preston
Journal:  Antimicrob Agents Chemother       Date:  1972-03       Impact factor: 5.191

10.  Antibacterial activity of cefamandole, a new cephalosporin antibiotic, compared with that of cephaloridine, cephalothin, and cephalexin.

Authors:  S Eykyn; C Jenkins; A King; I Phillips
Journal:  Antimicrob Agents Chemother       Date:  1973-06       Impact factor: 5.191

View more
  10 in total

1.  Pharmacokinetics of ceforanide.

Authors:  S Ripa; F La Rosa; A Ghezzi; M Prenna; M Pfeffer
Journal:  Antimicrob Agents Chemother       Date:  1982-02       Impact factor: 5.191

2.  Pharmacokinetics of ceforanide in patients with end stage renal disease on hemodialysis.

Authors:  J R Hess; S J Berman; W H Boughton; J G Sugihara; J E Musgrave; E G Wong; A M Siemsen
Journal:  Antimicrob Agents Chemother       Date:  1980-02       Impact factor: 5.191

Review 3.  Ceforanide. A review of its antibacterial activity, pharmacokinetic properties and clinical efficacy.

Authors:  D M Campoli-Richards; T E Lackner; J P Monk
Journal:  Drugs       Date:  1987-10       Impact factor: 9.546

4.  Ceforanide (BL-S786) in the treatment of community-acquired bacterial pneumonia.

Authors:  R J Wallace; R R Martin; S B Greenberg
Journal:  Infection       Date:  1979       Impact factor: 3.553

5.  Twice-daily intramuscular ceforanide therapy of Staphylococcus aureus endocarditis in parenteral drug abusers.

Authors:  R L Greenman; S M Arcey; D A Gutterman; R M Zweig
Journal:  Antimicrob Agents Chemother       Date:  1984-01       Impact factor: 5.191

Review 6.  Cefoxitin: a review of its antibacterial activity, pharmacological properties and therapeutic use.

Authors:  R N Brogden; R C Heel; T M Speight; G S Avery
Journal:  Drugs       Date:  1979-01       Impact factor: 9.546

7.  BL-S786 (ceforanide), a new parenteral cephalosporin: in vitro studies.

Authors:  S S Weaver; B M LeBlanc; G P Bodey
Journal:  Antimicrob Agents Chemother       Date:  1979-02       Impact factor: 5.191

8.  Treatment of cellulitis with ceforanide.

Authors:  D M Musher; V Fainstein; E J Young
Journal:  Antimicrob Agents Chemother       Date:  1980-02       Impact factor: 5.191

9.  Ceforanide: in vitro and clinical evaluation.

Authors:  K H Burch; D Pohlod; L D Saravolatz; T Madhavan; D Kiani; E L Quinn; R Del Busto; J Cardenas; E J Fisher
Journal:  Antimicrob Agents Chemother       Date:  1979-09       Impact factor: 5.191

10.  In vitro activity of LY127935.

Authors:  M Barza; F P Tally; N V Jacobus; S L Gorbach
Journal:  Antimicrob Agents Chemother       Date:  1979-09       Impact factor: 5.191

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.